

OncoQuest Inc.

Combinatorial Cancer
Immunotherapy

CORPORATE HEADQUARTERS

8123 Roper Road NW,
Edmonton, AB T6E 6S4
Tel: (780) 448-1400
www.oncoquestinc.com

Industry: Biotechnology/
Oncology

Shares outstanding:
8,476,036

- Quest PharmaTech: 50%
- Hepalink USA Inc.: 41%
- Others: 9%

Cash Available: US \$ 8.5M

Year End: January 31

OFFICERS AND DIRECTORS

Dr. Madi R. Madiyalakan, Ph.D
CEO and Director

Mr. Thomas Woo, M.Sc.
Vice President,
Product Development

Mr. Pierre Vermette, C.A.
Chief Financial Officer

Dr. Bin Huang, Ph.D
Chairman, Director

Mr. Shawn Lu, MBA
Director

Mr. Paul Van Damme, C.A.
Director

Mr. Xiangyu Gong, MBA
Director

CONTACT INFORMATION

Madi R. Madiyalakan, Ph.D,
Chief Executive Officer

e-mail: madi@oncoquestinc.com



Company Profile

OncoQuest is a private clinical stage biopharmaceutical company with a simple proprietary approach to the immunologic treatment of cancer, and we recently have shown survival benefits at an interim read out with our lead product in a randomized phase II trial in ovarian cancer. We acquired two complimentary proprietary platform technologies that are intended to improve the performance of current treatments of major solid tumors. Our product portfolio includes five monoclonal antibodies of the immunoglobulin G class ("IgG") and three (3) monoclonal antibodies of the immunoglobulin E Class ("IgE"), each specific to well-studied tumor markers. The antibodies are dosed as a vaccine to find their targets and initiate an immune attack on the associated cancer cells. We believe that the most successful therapy requires orchestrated combinatorial therapy against the cancer to overcome natural tumor associated immune suppression. Our technology has been shown in humans to work in this manner with our two lead antibodies. Furthermore, preclinical studies have demonstrated compatibility with both immune stimulating adjuvants and checkpoint inhibitors and identified the importance of schedule in combination with chemotherapy. Our products offer a simple off-the-shelf approach to initiate successful immunotherapy on a tumor antigen specific basis that is compatible with current standard treatments and complimentary to other emerging immunotherapeutic approaches.

OncoQuest recently announced positive interim clinical trial results from our 97 patients Phase II clinical study comparing chemoimmunotherapy (oregovomab + carboplatin + paclitaxel) versus chemotherapy alone in frontline ovarian cancer patients that may lead to a product registration trial in 2018. We are also conducting a series of phase I/II combinatorial clinical studies in several cancer indications, notably pancreatic and recurrent ovarian cancer to identify optimal immunotherapeutic conditions to treat cancer patients. We believe our technology has the potential for development to treat multiple types of cancer, such as ovarian, pancreas, breast, lung, stomach, multiple myeloma, and prostate cancers.

Our lead product candidate, oregovomab uses a proprietary monoclonal antibody of the IgG class that targets and binds to CA125 to induce anti-CA125 immunity. Our anti-MUC1 IgG is also at IND stage and additional IgG products recognize PSA, CA19.9 and TAG-72. Our antigen specific humanized IgE antibody platform can initiate immunity to the targets Her2/neu, MUC1 and PSA. Preclinical studies have been completed for all three IgE products and established all three agents can induce tumor specific immunity, can modify the biology of the stromal tissues surrounding individual cancers and facilitate penetration of the solid tumor matrix by cytotoxic agents, thus making this novel approach to cancer treatment extremely promising.

OncoQuest's technology is supported by an experienced management team, a global network of collaborators, an extensive patent portfolio and considerable scientific and clinical publications in peer reviewed journals.

OncoQuest's recent partnership with Shenzhen Hepalink Pharmaceutical Co., Ltd., a China based global pharmaceutical company, provides U.S. \$ 13,000,000 for the Company to accelerate progress in the development of this scientifically, clinically and commercially important approach to cancer management as combinatorial immunotherapy becomes a primary component of cancer treatment. In addition, OncoQuest has established a Joint Venture (OncoVent) with Shenzhen Hepalink to develop immunotherapeutic products for the Greater China market.



Antibody Based Combination Therapy to Enhance Tumor Specific Immunity and Clinical Outcome

Clinical and Pre-clinical Programs

Product Candidates	Clinical Program	Current Status
Anti-CA125 MAb oregovomab	Combination with front-line chemotherapy in advanced Ovarian Cancer (Phase IIb)	Positive interim results announced from the 97 patients study. Awaiting long term follow up results.
	Neoadjuvant immunotherapy in combination with Gemcitabine and radiotherapy in partially resectable CA125 positive Pancreatic Cancer (pilot study)	Physician sponsored clinical trial in progress at University of Nebraska Medical Center
	Combination with immunoadjuvant (TLR-3 agonist, Hiltonol®) in recurrent Ovarian Cancer setting	IND submitted to FDA on October 28, 2016. We received no comments from US FDA and intend to commence a Phase 1/2 study
	Combination with checkpoint inhibitor in recurrent Ovarian Cancer	Awaiting regulatory approval for initiation of physician sponsored trial in Singapore
Anti-MUC1 MAb with check point inhibitor and TLR3 agonist	Neoadjuvant Immunotherapy in combination with chemotherapy, check point inhibitor and/or Hiltonol®	Development of Phase II clinical protocol in progress. Additional pre-clinical studies in progress at University of Nebraska Medical Center
Product Candidates	Pre-Clinical Program	Current Status
Anti Her2/neu IgE MAb	Pharmacological efficacy studies to broaden the mechanistic understanding of IgE therapy in a human FcεR1-MUC1 double transgenic mouse model.	Anti Her2/neu IgE master cell bank development in progress. Disease target: Metastatic Breast Cancer

Selected References

Author	Journal	Reference	Topic
Braly et al	Journal of Immunotherapy	2009; 32:54-65	Front-line Chemo-Enhanced Immunotherapy (Study 18)
Gordon et al	Gynecologic Oncology	2004; 94:340-351	Recurrent Chemo-Enhanced Immunotherapy
Berek et al	Journal of Immunotherapy	2008; 31:207-214	Role of CA-125
de Bono et al	Annals of Oncology	2004; 15:1825-1833	Anti-MUC1 for T-cells Response / ELISPOT
Nicodemus et al	American Journal of Obstetrics & Gynecology	2010; 202(6): 608. e1-8.	Combination with TLR Agonist
Teo et al	Cancer Immunology & Immunotherapy	2012; 61: 2295 - 2309	Anti-hMUC1 IgE for Cancer Therapy
Daniels et al	Cancer Immunology & Immunotherapy	2012; 61: 991 - 1003	Anti Her2/neu IgE for Cancer Therapy
Nicodemus C	Immunotherapy	2015; 7(8): 923 - 39	Review of Antibody Based Immunotherapy

OncoQuest Clinical and Scientific Advisory Board Members

Dr. Christopher Nicodemus (Chair)
President and CSO,
AIT Strategies, US

Dr. Eric Shi, Ph.D.
Professor, Nanjing Medical University
Associate Dean, Academy of Clinical and Translational Research, Jiangsu Province

Professor William McGuire,
Massey Cancer Center, Virginia Commonwealth University, USA

Professor Ignace Vergote
Professor, Catholic University of Leuven, Belgium
Chairman, ENGOT

Professor Thomas Ehlen
Professor, University of British Columbia, Canada

Dr. Michael A Hollingsworth, Ph.D.
Professor, Eppley Institute University of Nebraska Medical Center, USA

Professor Roberto Angioli
Gynecology and Obstetrics, Campus Biomedico University of Rome, Italy

CONTACT INFORMATION

OncoQuest Inc.
8123 Roper Road NW
Edmonton, AB T6E 6S4
(780) 448-1400 ext.204
madi@oncoquestinc.com
www.oncoquestinc.com